|
PTPLB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.13080000310839E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.60750000047727E-07 |
| Normal-vs-Stage2 |
1.846980E-04 |
| Normal-vs-Stage3 |
3.90629995017377E-09 |
| Normal-vs-Stage4 |
1.64789999999027E-05 |
| Stage1-vs-Stage2 |
9.132400E-01 |
| Stage1-vs-Stage3 |
1.095240E-01 |
| Stage1-vs-Stage4 |
4.894200E-01 |
| Stage2-vs-Stage3 |
3.158400E-01 |
| Stage2-vs-Stage4 |
6.597600E-01 |
| Stage3-vs-Stage4 |
6.292000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.87789999503718E-08 |
| Normal-vs-AfricanAmerican |
6.560700E-03 |
| Normal-vs-Asian |
2.06339999999638E-05 |
| Caucasian-vs-AfricanAmerican |
4.446000E-01 |
| Caucasian-vs-Asian |
7.165400E-01 |
| AfricanAmerican-vs-Asian |
3.747800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.42260003777039E-09 |
| Normal-vs-Female |
4.29029999970965E-07 |
| Male-vs-Female |
8.372400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.13379999999264E-05 |
| Normal-vs-Age(41-60Yrs) |
1.38000000315941E-08 |
| Normal-vs-Age(61-80Yrs) |
1.09729999975272E-07 |
| Normal-vs-Age(81-100Yrs) |
2.435300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.644170E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.751030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.423400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.165000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.660000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.310800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.280240E-01 |
| Classical-VS-Follicular |
1.782440E-02 |
| Classical-VS-Other |
1.013370E-01 |
| Classical-VS-Normal |
3.89460000005393E-06 |
| Tall-VS-Follicular |
9.894400E-01 |
| Tall-VS-Other |
3.194800E-01 |
| Tall-VS-Normal |
3.54000000002408E-06 |
| Follicular-VS-Other |
3.812200E-01 |
| Follicular-VS-Normal |
2.18419999864494E-08 |
| Other-VS-Normal |
7.018700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65600000379129E-08 |
| Normal-vs-N1 |
4.1021999996893E-07 |
| N0-vs-N1 |
5.102400E-01 |
|
|
